Significance of Epstein-Barr virus (EBV) load and Interleukin-10 in post-transplant lymphoproliferative disorders

References

• Harris N L, Ferry J A, Swerdlow S H. Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. Seminars in Diagnostic Pathology 1997; 14: 8–14
   PubMed Web of Science ®Google Scholar
• Harris N L, Jaffe E S, Diebold J, Flandrin G, Muller-Hermelink H K, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clincal Advisory Committee Meeting-Airlie House, Virginia, November 1997. Journal of Clinical Oncology 1999; 17: 3835–3849
   PubMed Web of Science ®Google Scholar
• Middeldorp J M, Brink A ATP, Van den Brule A JC, Meijer C JLM. Pathogenic roles for Epstein-Barr virus (EBV) gene products in EBV-associated proliferative disorders. Critical Reviews in Oncology Hematology 2003; 45: 1–36
   PubMed Web of Science ®Google Scholar
• Tsai D E, Nearey M, Hardy C L, Tomaszewski J E, Kotloff R M, Grossman R A, et al. Use of EBV PCR for the diagnosis and monitoring of post-transplant lymphoproliferative disorder in adult solid organ transplant patients. American Journal of Transplantation 2002; 2: 946–954
   PubMed Web of Science ®Google Scholar
• Stevens S JC, Verschuuren E AM, Verkuijlen S AW, van den Brule A JC, Meijer C JLM, Middeldorp J M. Role of Epstein-Barr virus DNA load monitoring in prevention and early detection of post-transplant lymphoproliferative disease. Leukemia and Lymphoma 2002; 43: 831–840
   PubMed Web of Science ®Google Scholar
• Young L S, Murray P G. Epstein-Barr virus and oncogenesis: from latent genes to tumors. Oncogene 2003; 22: 5108–5121
   PubMed Web of Science ®Google Scholar
• Birkeland S A, Bendtzen K, Moller B, Hamilton Dutoit S, Andersen H K. Transplantation 1999; 67: 876–881
   PubMed Web of Science ®Google Scholar
• Garnier J L, Blanc Brunat N, Vivier G, Rousset F, Touraine J L. Interleukin-10 in Epstein-Barr virus-associated post-transplant lymphomas. Clinical Transplantation 1999; 13: 305–312
   PubMed Web of Science ®Google Scholar
• Wagner H J, Fischer L, Jabbs W J, Holbe M, Pethig K, Bucsky P. Longitudinal analysis of Epstein-Barr viral load in plasma and peripheral blood mononuclear cells of transplanted patients by real-time polymerase chain reaction. Transplantation 2002; 74: 656–664
   PubMed Web of Science ®Google Scholar
• Preiksaitis J K. New developments in the diagnosis and menagement of posttransplantation lymphoproliferative disorders in solid organ transplant recipients. Clinical Infectious Diseases 2004; 39: 1016–1023
   PubMed Web of Science ®Google Scholar
• Allen U, Hebert D, Petric M, Tellier R, Tran D, Superina R, et al. Utility of semiquantitative polymerase chain reaction for Epstein-Barr virus to measure virus load in pediatric organ transplant recipients with and without posttransplant lymphoproliferative disease. Clinical Infectious Diseases 2001; 33: 145–150
   PubMed Web of Science ®Google Scholar
• Gartner B C, Schafer H, Marggraff K, Eisele G, Schafer M, Roemer K, et al. Evaluation of use of Epstein-Barr viral load in patients after allogenic stem cell transplantation to diagnose and monitor postransplant lymphoproliferative disease. Journal of Clinical Microbiology 2002; 40: 351–358
   PubMed Web of Science ®Google Scholar
• Lucas K G, Burton R L, Zimmerman S E, Wang J, Cornetta K G, Robertson K A, et al. Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood 1998; 91: 3654–3661
   PubMed Web of Science ®Google Scholar
• Fellner M D, Durand K, Correa M, Bes D, Alonio L V, Teyssie A R, et al. A semiquantitative PCR method (SQ-PCR) to measure Epstein-Barr virus (EBV) load: its application in transplant patients. Journal of Clinical Virology 2003; 28: 323–330
   PubMed Web of Science ®Google Scholar
• Kimura H, Morita M, Yabuta Y, Kuzushima K, Kato K, Kojima S, et al. Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay. Journal of Clinical Microbiology 1999; 37: 132–136
   PubMed Web of Science ®Google Scholar
• Niesters H GM, van Esser J, Fries E, Wolthers K C, Cornelissen J, Osterhaus A DME. Development of a real-time quantitative assay for detection of Epstein-Barr virus. Journal of Clinical Microbiology 2000; 38: 712–715
   PubMed Web of Science ®Google Scholar
• Jabs W J, Hennig H, Kittel M, Pethig K, Smets F, Bucsky P, et al. Normalized quantification by real-time PCR of Epstein-Barr virus load in patients at risk for posttransplant lymphoproliferative disorders. Journal of Clinical Microbiology 2001; 39: 564–569
   PubMed Web of Science ®Google Scholar
• Stevens S JC, Verkuijlen S AWM, van den Brule A JC, Middeldrop J M. Comparison of quantitative competitive PCR with lightcycler-based PCR for measuring Epstein-Barr virus DNA load inclinical specimens. Journal of Clinical Microbiology 2002; 40: 3986–3992
   PubMed Web of Science ®Google Scholar
• Leung E, Shenton B K, Jackson G, Gould F K, Yap C, Talbot D. Use of real-time PCR to measure Epstein-Barr virus genomes in whole blood. Journal of Immunological Methods 2002; 270: 259–267
   PubMed Web of Science ®Google Scholar
• Brengel-Pesce K, Morand P, Schmuck A, Bourgeat M J, Buisson M, Bargues G, et al. Routine use of real-time quantitative PCR for laboratory diagnosis of Epstein-Barr virus infections. Journal of Medical Virology 2002; 66: 360–369
   PubMed Web of Science ®Google Scholar
• Matsukura T, Yokoi A, Egawa H, Kudo T, Kawashima M, Hirata Y, et al. Significance of serial real-time PCR monitoring of EBV genome load in living donor liver transplantation. Clinical Transplantation 2002; 16: 107–112
   PubMed Web of Science ®Google Scholar
• Meerbach A, Gruhn B, Egerer R, Reischl U, Zintl F, Wutzler P. Semiquantitative PCR analysis of Epstein-Barr virus DNA in clinical samples of patients with EBV-associated diseases. Journal of Medical Virology 2001; 65: 348–357
   PubMed Web of Science ®Google Scholar
• Rowe D T, Qu L, Reyes J, Jabbour N, Yunis E, Putnam P, et al. Use of quantitative competitive PCR to measure Epstein-Barr Virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders. Journal of Clinical Microbiology 1997; 35: 1612–1615
   PubMed Web of Science ®Google Scholar
• Mutimer D, Kaur N, Tang H, Singhal S, Shaw J, Whitehead L, et al. Quantification of Epstein-Barr virus DNA in the blood of adult liver transplant recipients. Transplantation 2000; 69: 954–959
   PubMed Web of Science ®Google Scholar
• Stevens S JC, Pronk I, Middeldrop J M. Toward standardization of Epstein-Barr virus DNA load monitoring: unfractionated whole blood as preferred clinical specimen. Journal of Clinical Microbiology 2001; 39: 1211–1216
   PubMed Web of Science ®Google Scholar
• Rowe D T, Webber S, Schauer E M, Reyes J, Green M. Epstein-Barr virus load monitoring: its role in the prevention and management of post-transplant lymphoproliferative disease. Transplant Infectious Disease 2001; 3: 79–87
   PubMedGoogle Scholar
• van Esser J WJ, Niesters H GM, van der Holt B, Meijer E, Osterhaus A DME, Gratama J W, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogenic stem cell transplantation. Blood 2002; 99: 4364–4369
   PubMed Web of Science ®Google Scholar
• Campe H, Jaeger G, Abou-Ajram C, Nitschko H, Griebel M, Montoya C, et al. Serial detection of Epstein-Barr virus DNA in sera and peripheral blood leukocyte samples of pediatric renal allograft recipients with persistent mononucleosis-like symptoms defines patients at risk to develop post-transplant lymphoproliferative disease. Pediatric Transplantation 2003; 7: 46–52
   PubMed Web of Science ®Google Scholar
• Orii T, Ohkohchi N, Kikuchi H, Koyamada N, Chubachi S, Satomi S, et al. Usfulness of quantitative real-time polymerase chain reaction in following up patients with Epstein-Barr virus infection after liver transplantation. Clinical Transplantation 2000; 14: 308–317
   PubMed Web of Science ®Google Scholar
• Limaye A P, Huang M -L, Atienza E E, Ferrenberg J M, Corey L. Detection of Epstein-Barr virus DNA in sera from transplant recipients with lymphoproliferative disorders. Journal of Clinical Microbiology 1999; 37: 1113–1116
   PubMed Web of Science ®Google Scholar
• Aalto S M, Juvonen E, Tarkkanen J, Volin L, Ruutu T, Mattila P S, et al. Lymphoproliferative disease after allogenic stem cell transplantation-pre-emtive diagnosis by quantification of Epstein-Barr virus DNA in serum. Journal of Clinical Virology 2003; 28: 275–283
   PubMed Web of Science ®Google Scholar
• Sirvent-von Bueltzingsloewen A, Morand P, Buisson M, Souillet G, Chambost H, Bosson J L, Bordigoni P. A prospective study of Epstein-Barr virus load in 85 hematopoietic stem cell transplants. Bone Marrow Transplantation 2002; 29: 21–28
   PubMed Web of Science ®Google Scholar
• Stevens S JC, Verschuuren E AM, Pronk I, Van der Bij W, Harmsen M C, The T H, et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 2001; 97: 1165–1171
   PubMed Web of Science ®Google Scholar
• Clave E, Agbalika F, Bajzik V, Peffault de Latour R, Trillard M, Rabian C, et al. Epstein-Barr virus (EBV) reactivation in allogenic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy. Transplantation 2004; 77: 76–84
   PubMed Web of Science ®Google Scholar
• Yang J, Tao Q, Flinn I W, Murray P G, Post L E, Ma H, et al. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: diseapparance after rituximab therapy does not predict clinical response. Blood 2000; 96: 4055–4063
   PubMed Web of Science ®Google Scholar
• Green M, Webber S A. EBV viral load monitoring: unanswered questions. American Journal of Transplantation 2002; 2: 894–895
   PubMed Web of Science ®Google Scholar
• Heslop H, Savoldo B, Rooney C M. Cellular therapy of Epstein-Barr-virus-associated post-transplant lymphoproliferative disease. Best Practice & Research Clinical Haematology 2004; 17: 401–413
   PubMed Web of Science ®Google Scholar
• Holmes R D, Sokol R J. Epstein-Barr virus and post-transplant lymphoproliferative disease. Pediatric Transplantation 2002; 6: 456–464
   PubMed Web of Science ®Google Scholar
• van Esser J WJ, van der Holt B, Meijer E, Niesters H GM, Trenschel R, Thijsen S FT, et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogenic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 2001; 98: 972–978
   PubMed Web of Science ®Google Scholar
• Orentas R J, Schauer D W, Jr, Ellis F W, Walczak J, Casper J T, Margolis D A. Monitoring and modulation of Epstein-Barr virus loads in pediatric transplant patients. Pediatric Transplantation 2003; 7: 305–314
   PubMed Web of Science ®Google Scholar
• Cesaro S, Murrone A, Mengoli C, Pillon M, Biasolo M A, Calore E, et al. The real-time polymerase chain reaction-guided modulation of immunosuppression enables the pre-emptive management of Epstein-Barr virus reactivation after allogenic haematopoietic stem cell transplantation. British Journal of Haematology 2004; 128: 224–233
   Web of Science ®Google Scholar
• Green M, Bueno J, Rowe D, Mazariegos G, Qu L, Abu-Almagd K, Reyes J. Predictive negative value of persistent low Epstein-Barr virus viral load after intestinal transplantation in children. Transplantation 2000; 70: 593–596
   PubMed Web of Science ®Google Scholar
• Scheenstra R, Verschuuren E AM, de Haan A, Slooff M JH, The T H, Bijleveld C MA, Verkade H J. The value of prospective monitoring of Epstein-Barr virus DNA in blood samples of pediatric liver transplant recipients. Transplant Infectious Disease 2004; 6: 15–22
   PubMedGoogle Scholar
• Holmes R D, Orban-Eller K, Karrer F R, Rowe D T, Narkewicz M R, Sokol R J. Response of elevated Epstein-Barr virus DNA levels to therapeutic changes in pediatric liver transplant patients: 56-month follow up and outcome. Transplantation 2002; 74: 367–372
   PubMed Web of Science ®Google Scholar
• Savoie A, Perpete C, Carpentier L, Joncas J, Alfieri C. Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease. Blood 1994; 83: 2715–2722
   PubMed Web of Science ®Google Scholar
• Smets F, Latinne D, Bazin H, Reding R, Otte J B, Buts J P, Sokal E M. Ratio between Epstein-Barr viral load ant anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation 2002; 73: 1603–1610
   PubMed Web of Science ®Google Scholar
• Carpentier L, Tapiero B, Alvarez F, Viau C, Alfieri C. Epstein-Barr virus (EBV) early-antigen serologic testing in conjunction with peripheral blood EBV DNA load as a marker for risk of posttransplantation lymphoproliferative disease. Journal of Infectious Disease 2003; 188: 1853–1864
   PubMed Web of Science ®Google Scholar
• Vossen M TM, Gent M R, Davin J C, Baars P A, Wertheim-van Dillen P ME, Weel J FL, et al. Spontaneous outgrowth of EBV-transformed B-cells reflects EBV-specific immunity in vivo; a useful tool in the follow-up of EBV-driven immunoproliferative disorders in allograft recipients. Transplant International 2004; 17: 89–96
   PubMed Web of Science ®Google Scholar
• Baudouin V, Dehee A, Pedron-Grossetete B, Ansart-Pirenne H, Haddad E, Maisin A, et al. Relationship between CD8 + T-cell phenotype and function, Epstein-Barr virus load, and clinical outcome in pediatric renal transplant recipients: a prospective study. Transplantation 2004; 77: 1706–1713
   PubMed Web of Science ®Google Scholar
• Nelson B P, Nalesnik M A, Bahler D W, Locker J, Fung J J, Swerdlow S H. Epstein-Barr virus-negative post-transplant lymphoproliferative disorders. A distinct entity?. American Journal of Surgical Pathology 2000; 24: 375–385
   PubMed Web of Science ®Google Scholar
• Muti G, Klersy C, Baldanti F, Granata S, Oreste P, Pezzetti L, et al. Epstein-Barr virus (EBV) laod and interleukin-10 in EBV-positive and EBV-negative post-transplant lymphoproliferative disorders. British Journal of Haematology 2003; 122: 927–933
   PubMed Web of Science ®Google Scholar
• Axelrod D A, Holmes R, Thomas S E, Magee J C. Limitations of EBV-PCR monitorino to detect EBV associated posttransplant lymphoproliferative disorder. Pediatric Transplantation 2003; 7: 223–227
   PubMed Web of Science ®Google Scholar
• Nuckols J D, Baron P W, Stenzel T T, Olatidoye B A, Tuttle-Newhall J E, Clavien P -A, et al. The pathology of liver-localized post-transplant lymphoproliferative disease. A report of three cases and a review of the literature. American Journal of Surgical Pathology 2000; 24: 733–741
   PubMed Web of Science ®Google Scholar
• Muti G, Mancini V, Veronese S, Poli F, Oreste P, Baldanti F, et al. Donor or recipient origin of posttransplant lymphoproliferative disorders in liver transplanted patients: two different, clinically relevant, patterns of disease. Blood 2003; 102, Abstract 2324
   PubMed Web of Science ®Google Scholar
• Baldanti F, Grossi P, Furione M, Simoncini L, Sarasini A, Comoli P, et al. High levels of Epstein-Barr virus DANN in blood of solid-organ transplant recipients and their value in predicting posttransplant lymphoproliferative disorders. Journal of Clinical Microbiology 2000; 38: 613–619
   PubMed Web of Science ®Google Scholar
• Loren A W, Porter D L, Stadtmauer E A, Tsai D E. Post-transplant lymphoproliferative disorder: a review. Bone Marrow Transplantation 2003; 31: 145–155
   PubMed Web of Science ®Google Scholar
• Babcock G J, Decker L L, Freeman R B, Thorley-Lawson D A. Epstein-Barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. Journal of Experimental Medicine 1999; 190: 567–576
   PubMed Web of Science ®Google Scholar
• Hopwood P A, Brooks L, Parratt R, Hunt B J, Maria B, Alero B J, et al. Persistent Epstein-Barr virus infection: unrestricted latent and lytic viral gene expression in healty immunosuppressed transplant recipients. Transplantation 2002; 74: 194–202
   PubMed Web of Science ®Google Scholar
• Vajro P, Lucariello S, Migliaro F, Sokal E, Gridelli B, Vegnente A, et al. Predictive value of Epstein-Barr virus genome copy number and BZLF1 expression in blood lymphocytes of transplant recipients at risk for lymphoproliferative disease. The Journal of Infectious Diseases 2000; 181: 2050–2054
   PubMed Web of Science ®Google Scholar
• Randhawa P S, Demetris A J, Nalesnik M A. The potential role of cytokines in the pathogenesis of Epstein-Barr virus associated post-transplant lymphoproliferative disease. Leukemia and Lymphoma 1994; 15: 383–387
   PubMed Web of Science ®Google Scholar
• Tosato G, Teruya Feldstein J, Setsuda J, Pike S E, Jones K D, Jaffe E S. Post-transplant lymphoproliferative disease (PTLD): lymphokine production and PTLD. Springer Seminars in Immunpathology 1998; 20: 405–423
   PubMed Web of Science ®Google Scholar
• Ohga S, Nomura A, Takada H, Hara T. Immunological aspects of Epstein-Barr virus infection. Critical Reviews in Oncology/Hematology 2002; 44: 203–215
   PubMed Web of Science ®Google Scholar
• Nalesnik M A, Zeevi A, Randhawa P S, Faro A, Spichty K J, Demetris A J, et al. Cytokine mRNA profiles in Epstein-Barr virus-associated post-transplant lymphoproliferative disorders. Clinical Transplantation 1999; 13: 39–44
   PubMed Web of Science ®Google Scholar
• Tanner J E, Alfieri C. The Epstein-Barr virus and post-transplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis. Transplant Infectious Disease 2001; 3: 60–69
   PubMedGoogle Scholar
• Voorzanger N, Blay J Y. Interleukin 10 and Hodgkin's lymphomas. Cancer in transplantation. Prevention and treatment, J L Touraine, J Traeger, H Betuel, J M Dubrenand, J P Revillard, C Dupuy. Kluwer Academic Publisher, Dordrecht 1996; 229–241
   Google Scholar
• Mocellin S, Panelli M C, Wang E, Nagorsen D, Marincola F M. The dual role of IL-10. Trends in Immunology 2003; 24: 36–43
   PubMed Web of Science ®Google Scholar
• Burdin N, Rousset F, Banchereau J. B-cell-derived IL-10: production and function. Methods 1997; 11: 98–111
   PubMed Web of Science ®Google Scholar
• Bejarano M T, Masucci M G. Interleukin-10 abrogates the inibition of Epstein-Barr virus-induced B-cell transformation by memory T-cell responses. Blood 1998; 92: 4256–4262
   PubMed Web of Science ®Google Scholar
• Mahot S, Sergeant A, Drouet E, Gruffat H. A novel function for the Epstein-Barr virus transcription factor EB1/Zta: induction of transcription of the hIL-10 gene. Journal of General Virology 2003; 84: 965–974
   PubMed Web of Science ®Google Scholar
• Duddy M E, Alter A, Bar-Or A. Distinct profiles of human B cell effector cytokines: a role in immune regulation?. The Journal of Immunology 2004; 172: 3422–3427
   PubMed Web of Science ®Google Scholar
• Hayes D P, Brink A ATP, Vervoort M BHJ, Middeldorp J M, Meijer C JLM, van den Brule A JC. Expression of Epstein-Barr virus (EBV) transcripts encoding homologues to important human proteins in diverse EBV associated diseases. Journal of Clinical Pathology: Molecular Pathology 1999; 52: 97–103
   Web of Science ®Google Scholar
• Fickenscher H, Hor S, Kupers H, Knappe A, Wittmann S, Sticht H. The interleukin-10 family of cytokines. Trends in Immunology 2002; 23: 89–96
   PubMed Web of Science ®Google Scholar
• Ryon J J, Hayward S D, MacMahon E ME, Mann R B, Ling Y, Charache P, et al. In situ detection of lytic Epstein-Barr virus infection: expression of the NotI early gene and viral interleukin-10 late gene in clinical specimens. The Journal of Infectious Diseases 1993; 168: 345–351
   PubMed Web of Science ®Google Scholar
• Kitagawa N, Goto M, Kurozumi K, Maruo S, Fukayama M, Naoe T, et al. Epstein-Barr virus-encoded poly(A)-RNA supports Burkitt's lymphoma growth through interleukin-10 induction. The EMBO Journal 2000; 19: 6742–6750
   PubMed Web of Science ®Google Scholar
• Herbst H, Foss H D, Samol J, Araujo I, Klotzbach H, Krause H, et al. Frequent expression of interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin's disease. Blood 1996; 87: 2918–2929
   PubMed Web of Science ®Google Scholar
• Dukers D F, Jaspars L H, Vos W, Oudejans J J, Hayes D, Cillessen S, et al. Quantitative immunohistochemical analysis of cytokine profiles in Epstein-Barr virus-positive and -negative cases of Hodgkin's disease. Journal of Pathology 2000; 190: 143–149
   PubMed Web of Science ®Google Scholar
• Ohga S, Nomura A, Takada H, Tanaka T, Furuno K, Takahata Y, et al. Dominant expression of interleukin-10 and transforming growth factor-β genes in activated T-cells of chronic active Epstein-Barr virus infection. Journal of Medical Virology 2004; 74: 449–458
   PubMed Web of Science ®Google Scholar
• Cortes J, Kurzrock R. Interleukin-10 in non-Hodgkin's lymphoma. Leukemia and Lymphoma 1997; 26: 251–259
   PubMed Web of Science ®Google Scholar
• Breen C E, Boscardin W J, Detels R, Jacobson L P, Smith M W, O'Brien S J, et al. Non-Hodgkin's B cell lymphoma in persons with acquired immunodeficiency syndrome is associated with increased serum levels of IL10, or the IL10 promoter – 592 C/C genotype. Clinical Immunology 2003; 109: 119–129
   PubMed Web of Science ®Google Scholar
• Kanegane H, Wakiguchi H, Kanegane C, Kurashige T, Tosato G. Viral interleukin-10 in chronic active Epstein-Barr virus infection. The Journal of Infectious Disease 1997; 176: 254–257
   PubMed Web of Science ®Google Scholar
• Xu Z G, Iwatsuki K, Oyama N, Ohtsuka M, Satoh M, Kikuchi S, et al. The latency pattern of Epstein-Barr virus infection and viral IL-10 expression in cutaneous natural killer/T-cell lymphomas. British Journal of Cancer 2001; 84: 920–925
   PubMed Web of Science ®Google Scholar
• Beck A, Pazolt D, Grabenbauer G G, Nicholls J M, Herbst H, Young L S, et al. Expression of cytokine and chemokine genes in Epstein-Barr virus-associated nasooharyngeal carcinoma: comparison with Hodgkin's disease. Journal of Pathology 2001; 194: 145–151
   PubMed Web of Science ®Google Scholar
• Herling M, Rassidakis G Z, Medeiros L J, Vassilakopoulos T P, Kliche K O, Nadali G, et al. Expression of Epstein-Barr virus latent membrane protein-1 in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma: associations with presenting features, serum interleukin 10 levels, and clinical outcome. Clinical Cancer Research 2003; 9: 2114–2120
   PubMed Web of Science ®Google Scholar
• Fassone L, Gaidano G, Ariatti C, Vivenza D, Capello D, Gloghini A, et al. The role of cytokines in the pathogenesis and management of Aids-related lymphomas. Leukemia and Lymphoma 2000; 38: 481–488
   PubMed Web of Science ®Google Scholar
• Sarris A H, Kliche K O, Pethambaram P, Preti A, Tucker S, Jackow C, et al. Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure-free survival. Annals of Oncology 1999; 10: 433–440
   PubMed Web of Science ®Google Scholar
• Bohlen H, Kessler M, Sextro M, Diehl V, Tesch H. Poor clinical outcome of patients with Hodgkin's disease and elevated interleukin-10 serum levels. Clinical significance of interleukin-10 serum levels for Hodgkin's disease. Annals of Hematology 2000; 79: 110–113
   PubMed Web of Science ®Google Scholar
• Vassilakopoulos T P, Nadali G, Angelopoulou M K, Siakantaris M P, Dimopoulou M N, Kontopidou F N, et al. Serum interleukin-10 levels are an independent prognostic factor for patients with Hodgkin's lymphoma. Hematologica 2001; 86: 274–281
   PubMed Web of Science ®Google Scholar
• Ozdemir F, Aydin F, Yilmaz M, Kavgaci H, Bektas O, Yavuz M N, Yavuz A A. The effects of IL-2, IL-6 and IL-10 levels on prognosis in patients with aggressive non-Hodgkin's lymphoma (NHL). Journal of Experimental and Clinical Cancer Research 2004; 23: 485–488
   PubMed Web of Science ®Google Scholar
• Beatty P R, Krams S M, Martinez O M. Involvement of IL-10 in the autonomous growth of EBV- transformed B cell lines. The Journal of Immunology 1997; 158: 4045–4051
   PubMed Web of Science ®Google Scholar
• Hornef M W, Bein G, Wilhelm D, Fricke L, Kirchner H. ICAM-1, soluble-CD23, and interleukin-10 concentrations in serum in renal-transplant recipients with Epstein-Barr virus reactivation. Clinical and Diagnostic Laboratory Immunology 1997; 4: 545–549
   PubMedGoogle Scholar
• Muti G, Cantoni S, Rossi V, Granata S, D'Avanzo G, Pezzetti L, et al. IL-10 serum levels in lymphomas of immunocompromised and immunocompetent patients. The Hematology Journal 2001; I(Suppl I), Abstract 499
   Google Scholar
• Wagner H J, Cheng Y C, Huls M H, Gee A P, Kuehnle I, Krance R A, et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004; 103: 3979–3981
   PubMed Web of Science ®Google Scholar